Literature DB >> 11170054

Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes.

A L Connor1, D J Bevitt, G L Toms.   

Abstract

The fusion glycoprotein, F, of human respiratory syncytial virus is a principal target of neutralising antibodies and an important protective immunogen. Among sub-group A strains of the virus the F gene is highly conserved. A comparison of F gene sequences of two sub-group B strains, 8/60 and 18537, indicates that the gene also is conserved within this sub-group. However, both limited sequence variability and antigenic variation occurs between F genes from different virus sub-groups. Such variability may be important in the failure of natural- and vaccine-induced immunity and it is thus important to identify the variable epitopes. Three anti-F MAbs exhibiting sub-group specific neutralisation and binding to recombinant F glycoprotein were studied. Comparison of A2 and 8/60 F gene sequences revealed 64 predicted variant amino acids. In order to map the variant amino acids responsible for sub-group specific binding, three sets of chimaeric genes, in which different domains of A2 and 8/60 F were exchanged, were created and expressed. Sub-group specificity mapped to the N-terminal region of F1 for two MAbs (RS2B8 and RS348) and to the C-terminal region for the third. By using site-directed mutagenesis, sub-group specific binding of MAbs RS2B8 and RS348 was attributed to a predicted loop region between residues 200 and 216. This loop carried four residues variant between the sub-groups. Change of at least two was necessary to abrogate MAb binding. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170054

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

2.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

3.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Authors:  Ivy Widjaja; Oliver Wicht; Willem Luytjes; Kees Leenhouts; Peter J M Rottier; Frank J M van Kuppeveld; Bert Jan Haijema; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

4.  Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.

Authors:  Anne M Hause; David M Henke; Vasanthi Avadhanula; Chad A Shaw; Lorena I Tapia; Pedro A Piedra
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

5.  Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.

Authors:  Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.